Mutations in the Jak-STAT pathway have shown evidence in contributing to EITL with Jak3 mutations accounting for 2 out of 4 tumor samples (alterations occurring in 2 distinct activating positions: V674A and M411I). This evidence concerns the gene JAK3 and neoplasm.